SCHEMBL3088747

SCHEMBL3088747

O=C(c1cc(-c2ccc[se]2)n(-c2ccc(Cl)cc2Cl)n1)N1CCCCC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 1/20 0.58
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
LMNA P02545 1/20 0.58
MAPT P10636 1/20 0.58
HTT P42858 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
CNR1 P21554 2/20 0.52
MALT1 Q9UDY8 1/20 0.51
HPGD P15428 1/20 0.48
MARS1 P56192 5/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
RPA1 P27694 1/20 0.47
CHRNA7 P36544 1/20 0.44
CNR2 P34972 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3087783 0.85 CNR1 (0.73) CNR1CNR2
SCHEMBL3100250 0.83 RPA1 (0.54) SMPD1MEN1KMT2ALMNAMAPT
SCHEMBL3097503 0.83 RPA1 (0.67) SMPD1MEN1KMT2ALMNAMAPT
SCHEMBL3092456 0.80 CNR1 (0.54) CNR1CNR2
SCHEMBL3095089 0.79 CNR1 (0.53) CNR1NPC1RAB9ACNR2
SCHEMBL3088748 0.78 MEN1 (0.56) SMPD1MEN1KMT2ALMNAMAPT
SCHEMBL3091499 0.77 CNR1 (0.60) SMPD1MEN1KMT2ALMNAMAPT
SCHEMBL3092493 0.77 FAAH (0.53) MEN1KMT2ALMNAMAPTMARS1
SCHEMBL3100215 0.69 CNR1 (0.78) LMNAMAPTCNR1CNR2
SCHEMBL30402321 0.69 GPR119 (0.53) MEN1KMT2ALMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803799-B2 such as 1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-5-(selenophen-2-yl)-1H-pyrazole-3-carboxamide, used for treating cannabinoid-receptor mediated disorders selected from obesity, metabolic syndrome, drug abuse and dependence or neuropathic pain NATIONAL HEALTH RESEARCH INSTITUTES (TW) 2010-09-28 US disclosed
US-20080021031-A1 SELENOPHENE COMPOUNDS NATIONAL HEALTH RESEARCH INSTITUTE (TW) 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021031-A1 SELENOPHENE COMPOUNDS CNR2, CNR1, SELENOI SMPD1 466/4885MEN1 1271/4885KMT2A 1718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.